{"entity":{"id":"oncodetect","kind":"drug","name":"Oncodetect","aka":[],"tldr":"Exact Sciences' entry into the leftover-cancer blood test market, launched in 2025 for bowel cancer follow-up.","summary":"Oncodetect launched in 2025 with initial validation in stage II-IV colorectal cancer, where the company reported that ctDNA positivity after surgery and during surveillance was strongly associated with recurrence, and Medicare coverage for colorectal surveillance followed. Exact Sciences has Cologuard's primary-care channel and the Oncotype DX oncology sales force behind it, which makes the test a commercial rather than technical challenge to Signatera. Broader indications and interventional trials are pending.","status":"emerging","asOf":"2026-09-10","links":[{"label":"Exact Sciences: Oncodetect","url":"https://www.exactsciences.com/"}],"tags":["test"],"related":["signatera"],"cancers":["colorectal"],"sections":[],"technologies":["mrd-testing","liquid-biopsy"],"targets":[],"drugs":[],"companies":["exact-sciences"],"institutions":[],"pathways":[],"terms":["mrd","ctdna"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019"],"journals":[],"dependsOn":[],"notes":["What a result means: the same as other tumour-informed MRD tests; ask whether a positive result would change your treatment before having it."],"brand":"Oncodetect","modality":"Tumour-informed ctDNA minimal residual disease test","mechanism":"Whole-exome sequencing of tumour tissue designs a patient-specific panel of up to 200 variants tracked in plasma by targeted sequencing.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/oncodetect/","neighbours":{"drug":[{"id":"signatera","kind":"drug","name":"Signatera","route":"/drugs/signatera/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"exact-sciences","kind":"company","name":"Exact Sciences (Abbott)","route":"/companies/exact-sciences/"}],"term":[{"id":"ctdna","kind":"term","name":"Circulating tumour DNA (ctDNA)","route":"/terms/ctdna/"},{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"paper":[{"id":"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019","kind":"paper","name":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","route":"/key-papers/paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019/"}],"biomarker":[{"id":"ctdna-mrd-positive","kind":"biomarker","name":"ctDNA MRD positivity (molecular residual disease after curative treatment)","route":"/biomarkers/ctdna-mrd-positive/"}]}}